Lyka Labs Amalgamation Scheme with Lyka Exports Becomes Effective from April 8, 2026
Lyka Labs Limited's scheme of amalgamation with Lyka Exports Limited has become effective from April 8, 2026, following NCLT approval on March 16, 2026, and subsequent filing with the Registrar of Companies. The amalgamation has resulted in an increase of the company's authorized share capital to Rs.59,00,00,000, comprising 5,70,00,000 equity shares of Rs.10.00 each and 2,00,000 redeemable preference shares of Rs.100.00 each. The appointed date for the scheme is April 1, 2022.
*this image is generated using AI for illustrative purposes only.
Lyka Labs Limited has successfully completed its amalgamation with Lyka Exports Limited, with the scheme becoming effective from April 8, 2026. The company informed the stock exchanges about this significant corporate development through a regulatory filing under SEBI Listing Regulations.
NCLT Approval and Implementation Timeline
The scheme of amalgamation received judicial approval from the National Company Law Tribunal, Ahmedabad Bench on March 16, 2026. The company received the certified true copy of the NCLT order on March 24, 2026. Subsequently, both the transferor company (Lyka Exports Limited) and the transferee company (Lyka Labs Limited) filed the certified copy with the Registrar of Companies, Ahmedabad on April 8, 2026.
| Parameter: | Details |
|---|---|
| NCLT Order Date: | March 16, 2026 |
| Certified Copy Received: | March 24, 2026 |
| ROC Filing Date: | April 8, 2026 |
| Scheme Effective Date: | April 8, 2026 |
| Appointed Date: | April 1, 2022 |
Authorized Share Capital Enhancement
Following the effectiveness of the amalgamation scheme, Lyka Labs Limited's authorized share capital has been automatically increased by the aggregate authorized share capital of Lyka Exports Limited. The company's Memorandum of Association has been amended to reflect this change in Clause V.
| Share Type: | Number of Shares | Face Value | Amount |
|---|---|---|---|
| Equity Shares: | 5,70,00,000 | Rs.10.00 each | Rs.57,00,00,000 |
| Redeemable Preference Shares: | 2,00,000 | Rs.100.00 each | Rs.2,00,00,000 |
| Total Authorized Capital: | Rs.59,00,00,000 |
Corporate Structure Impact
The amalgamation involves Lyka Exports Limited as the transferor company merging with Lyka Labs Limited as the transferee company. This corporate restructuring affects both companies' shareholders and creditors as per the approved scheme. The appointed date of April 1, 2022, indicates the effective date from which the financial and operational integration is considered for accounting and legal purposes.
The completion of this amalgamation represents a significant milestone in Lyka Labs Limited's corporate evolution, consolidating operations and potentially creating synergies between the merged entities. The company has fulfilled all regulatory requirements and obtained necessary approvals to execute this corporate restructuring successfully.
Historical Stock Returns for Lyka Labs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.45% | +3.03% | +1.26% | -39.42% | -45.00% | +120.04% |
What operational synergies and cost savings is Lyka Labs expecting to achieve from this amalgamation in the next fiscal year?
How will the increased authorized share capital of Rs. 590 crores be utilized for future expansion or strategic initiatives?
Will this corporate restructuring lead to any changes in Lyka Labs' business segments or market positioning in the pharmaceutical industry?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
